21 news items
AbbVie Is 'Successfully Positioned To Absorb Humira Biosimilar Erosion': Analyst
ABBV
BMY
17 May 24
to assess antipsychotic treatment efficacy.
“When we compare the two products, we believe emraclidine differentiates by its
Bristol Myers Squibb Presents New 4-Year Sotyktu Data Demonstrate Durable Response Rates And Consistent Safety In Moderate-To-Severe Plaque Psoriasis
BMY
16 May 24
, and 57.2% for static Physician's Global Assessment (sPGA) 0/1 (clear/almost clear), using modified nonresponder imputation (mNRI). The safety profile
New Four-Year Sotyktu (deucravacitinib) Data Demonstrate Durable Response Rates and Consistent Safety in Moderate-to-Severe Plaque Psoriasis
BMY
16 May 24
for Psoriasis Area and Severity Index (PASI) 75 and 90 were 71.7% and 47.5%, respectively, and 57.2% for static Physician's Global Assessment (sPGA) 0/1
Bristol Myers Squibb's CAR T Cell Therapy Breyanzi Approved by the U.S. Food and Drug Administration for Relapsed or Refractory Follicular Lymphoma
BMY
15 May 24
or complete response per Lugano criteria as assessed by an Independent Review Committee (IRC). The complete response (CR) rate was 73.4% (95% CI: 63.3
Peeling Back The Layers: Exploring Bristol-Myers Squibb Through Analyst Insights
BMY
26 Apr 24
on the current state of the company.
Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform
aordqg
BMY
26 Apr 24
of overall survival (OS) and progression-free survival (PFS) as assessed by Blinded Independent Central Review (BICR). With a median follow up
oygz5xap
BMY
25 Apr 24
as assessed
1geuil5y9j0hmbft8434cqftm0w6hb2 t8ssi3u3p47t2spmtqo4buo0bl0
BMY
8 Apr 24
of overall response rate.
The study remains ongoing to assess the additional key secondary endpoint of overall survival.
In 2022
dvzfjlwqntnch64ted8kiomzp7yr6mq8qhy0e448xhnyzq
BMY
6 Apr 24
meaningful changes in movement disorder scale scores over 52 weeks (Oral Session: New Pharmacological Treatments and Assessments and Poster F74
otqnavoxfp3osytgnr
BMY
2 Apr 24
assessment to understand evolving stakeholder views and ensure its business priorities
lgmo z2vs
BMY
ZLAB
1 Apr 24
).
The study remains ongoing to assess the additional key secondary endpoint of overall survival.
Results showed that Krazati
odbarem0ac2d9qs5pie7h2yuahcns74t5ymsj5cj7q2 3orx3x4r3
BMY
CATX
LNTH
28 Mar 24
feasibility assessments on additional sites.Preliminary results from Cohorts 1 and 2 of the Phase 1/2a trial are expected in the third
og6s6go2wcyq68ffudx 47xoanzw9izuvzbziceumzi0nb2qg
BMY
25 Mar 24
.
Echocardiogram assessments of LVEF are required prior to and during treatment with CAMZYOS. Initiation of CAMZYOS in patients
p7bid
BMY
14 Mar 24
escalation portion of the study assessed the safety and recommended dose for the subsequent Phase 2 expansion cohort. The Phase 2 portion of the study
v7m6l9qpohufp 2en2z
BMY
7 Mar 24
overall survival (OS) and progression-free survival (PFS) assessed by Blinded Independent Central Review (BICR